International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement

Autoimmunity Reviews

Volumn 15, Issue 12, 2016, Pages 1145-1160

  Ferri, Clodoveo ^a   Ramos Casals, Manuel ^b   Zignego, Anna Linda ^c   Arcaini, Luca ^d,e   Roccatello, Dario ^f   Antonelli, Alessandro ^g   Saadoun, David ^m,n,o,p   Desbois, Anne Claire ^m,n,o,p   Sebastiani, Marco ^a   Casato, Milvia ^h   Lamprecht, Peter ⁱ   Mangia, Alessandra ^j   Tzioufas, Athanasios G ^k   Younossi, Zobair M ^l   Cacoub, Patrice ^m,n,o,p  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITY OF FLORENCE   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

^e FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^f UNIVERSITY OF TURIN   (Italy)

^g UNIVERSITY OF PISA   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ UNIVERSITY OF LÜBECK   (Germany)

^j CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^k UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^l INOVA FAIRFAX HOSPITAL   (United States)

^m SORBONNE UNIVERSITÉ   (France)

ⁿ UMR S 959 ^*  (France)

^o CNRS   (France)

^p PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

more..

Author keywords

Arthritis; Autoimmunity; Diabetes; Diagnostic guidelines; Extrahepatic disorders; HCV; Hepatitis; Hepatitis C virus; Lymphoma; Mixed cryoglobulinemia; Neuropathy; Porphyria; Sicca syndrome; Sj gren's syndrome; Thyroid; Vasculitis

Indexed keywords

ARTHRALGIA; CHRONIC INFLAMMATION; CLINICAL FEATURE; CLINICAL OUTCOME; COGNITIVE DEFECT; CONSENSUS; DISEASE SEVERITY; EARLY DIAGNOSIS; FOLLOW UP; HEPATITIS C; HUMAN; IMMUNE DYSREGULATION; NEOPLASM; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; REVIEW; SJOEGREN SYNDROME; VASCULITIS; COMPLICATION; HEALTH CARE PLANNING; HEPACIVIRUS; METABOLISM;

HEALTH PLANNING GUIDELINES; HEPACIVIRUS; HEPATITIS C; HUMANS;

EID: 84995632267     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2016.09.006     Document Type: Review

References (166)

1. [1] Ferri, C., Sebastiani, M., Giuggioli, D., Colaci, M., Fallahi, P., Piluso, A., et al. Hepatitis C virus syndrome: a constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin's lymphoma, and cancer. World J Hepatol 7 (2015), 327–343.
2. [2] Cacoub, P., Gragnani, L., Comarmond, C., Zignego, A.L., Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis 46:Suppl. 5 (2014), S165–S173.
3. [3] Ramos-Casals, M., Stone, J.H., Cid, M.C., Bosch, X., The cryoglobulinaemias. Lancet 379 (2012), 348–360.
4. [4] Ferri, C., Zignego, A.L., Pileri, S.A., Cryoglobulins. J Clin Pathol 55 (2002), 4–13.
5. [5] Cacoub, P., Comarmond, C., Domont, F., Savey, L., Saadoun, D., Cryoglobulinemia vasculitis. Am J Med 128 (2015), 950–955.
6. [6] Zignego, A.L., Ferri, C., Pileri, S.A., Caini, P., Bianchi, F.B., Italian Association of the Study of Liver Commission of Extrahepatic Manifestations of HCV infection, Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis 39 (2007), 2–17.
7. [7] Westbrook, R.H., Dusheiko, G., Natural history of hepatitis C. J Hepatol 61 (2014), S58–S68.
8. [8] Zignego, A.L., Wojcik, G.L., Cacoub, P., Visentini, M., Casato, M., Mangia, A., et al. Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis. Genes Immun 15 (2014), 500–505.
9. [9] Ferri, C., Sebastiani, M., Antonelli, A., Colaci, M., Manfredi, A., Giuggioli, D., Current treatment of hepatitis C-associated rheumatic diseases. Arthritis Res Ther, 14, 2012, 215.
10. [10] Ferri, C., Sebastiani, M., Giuggioli, D., Cazzato, M., Longombardo, G., Antonelli, A., et al. Mixed cryoglobulinemia: demographic, clinical, and serological features, and survival in 231 patients. Semin Arthritis Rheum 33 (2004), 355–374.
11. [11] Negro, F., Forton, D., Craxì, A., Sulkowski, M.S., Feld, J.J., Manns, M.P., Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology 149 (2015), 1345–1360.
12. [12] Choo, G.L., Kuo, G., Weiner, A.J., Overby, L.R., Bradley, D.W., Houghton, M., Isolation of a cDNA clone derived from a blood-borne non-A non-B viral hepatitis genome. Science 244 (1989), 359–361.
13. [13] Ferri, C., Greco, F., Longombardo, G., Palla, P., Marzo, E., Moretti, A., et al. Association between hepatitis C virus and mixed cryoglobulinemia. Clin Exp Rheumatol 9 (1991), 621–624.
14. [14] Monti, G., Galli, M., Invernizzi, F., Pioltelli, P., Saccardo, F., Monteverde, A., et al. Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. QJM 88 (1995), 115–126.
15. [15] Ferri, C., Caracciolo, F., Zignego, A.L., La Civita, L., Monti, M., Longombardo, G., et al. Hepatitis C virus infection in patients with non-Hodgkin's lymphoma. Br J Haematol 88 (1994), 392–394.
16. [16] Peveling-Oberhag, J., Arcaini, L., Hansmann, M.L., Zeuzem, S., Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol 59 (2013), 169–177.
17. [17] De Vita, S., Soldano, F., Isola, M., Monti, G., Gabrielli, A., Tzioufas, A., et al. Preliminary classification criteria for the cryoglobulinaemic vasculitis. Ann Rheum Dis 70 (2011), 1183–1190.
18. [18] Quartuccio, L., Isola, M., Corazza, L., Ramos-Casals, M., Retamozo, S., Ragab, G.M., et al. Validation of the classification criteria for cryoglobulinaemic vasculitis. Rheumatology 53 (2014), 2209–2213.
19. [19] Vitali, C., Bombardieri, S., Jonsson, R., Moutsopoulos, H.M., Alexander, E.L., Carsons, S.E., et al., European Study Group on Classification Criteria for Sjögren's Syndrome, Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61 (2002), 554–558.
20. [20] Brito-Zerón, P., Theander, E., Baldini, C., Seror, R., Retamozo, S., Quartuccio, L., et al. Early diagnosis of primary Sjögren's syndrome: EULAR-SS task force clinical recommendations. Expert Rev Clin Immunol 12 (2016), 137–156.
21. [21] Aletaha, D., Neogi, T., Silman, A.J., Funovits, J., Felson, D.T., Bingham, C.O. III, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62 (2010), 2569–2581.
22. [22] Petri, M., Orbai, A.M., Alarcón, G.S., Gordon, C., Merrill, J.T., Fortin, P.R., et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64 (2012), 2677–2686.
23. [23] Hernández-Rodríguez, J., Alba, M.A., Prieto-González, S., Cid, M.C., Diagnosis and classification of polyarteritis nodosa. J Autoimmun 48 (2014), 84–89.
24. [24] Monti, G., Saccardo, F., Castelnovo, L., Novati, P., Sollima, S., Riva, A., et al. Prevalence of mixed cryoglobulinaemia syndrome and circulating cryoglobulins in a population-based survey: the Origgio study. Autoimmun Rev 13 (2014), 609–614.
25. [25] Younossi, Z., Park, H., Henry, L., Adeyemi, A., Stepanova, M., Extra-hepatic manifestations of hepatitis C—a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology 150 (2016), 1599–1608.
26. [26] Lormeau, C., Falgarone, G., Roulot, D., Boissier, M.C., Rheumatologic manifestations of chronic hepatitis C infection. Joint Bone Spine 73 (2006), 633–638.
27. [27] Sebastiani, M., Giuggioli, D., Colaci, M., Fallahi, P., Gragnani, L., Antonelli, A., et al. HCV-related rheumatic manifestations and therapeutic strategies. Curr Drug Targets, 2015 [PMID: 26343108].
28. [28] Fadda, P., La Civita, L., Zignego, A.L., Ferri, C., Hepatitis C virus infection and arthritis. A clinico-serological investigation of arthritis in patients with or without cryoglobulinemic syndrome. Reumatismo 54 (2002), 316–323.
29. [29] Palazzi, C., D'Angelo, S., Olivieri, I., Hepatitis C virus-related arthritis. Autoimmun Rev 8 (2008), 48–51.
30. [30] Ferri, C., Govoni, M., Calabrese, L., The A, B, Cs of viral hepatitis in the biologic era. Curr Opin Rheumatol 22 (2010), 443–450.
31. [31] Ramos-Casals, M., De Vita, S., Tzioufas, A.G., Hepatitis C virus, Sjögren's syndrome and B-cell lymphoma: linking infection, autoimmunity and cancer. Autoimmun Rev 4 (2005), 8–15.
32. [32] Ramos-Casals, M., Muñoz, S., Zerón, P.B., Hepatitis C virus and Sjögren's syndrome: trigger or mimic?. Rheum Dis Clin North Am 34 (2008), 869–884.
33. [33] Brito-Zerón, P., Gheitasi, H., Retamozo, S., Bové, A., Londoño, M., Sánchez-Tapias, J.M., et al. How hepatitis C virus modifies the immunological profile of Sjögren syndrome: analysis of 783 patients. Arthritis Res Ther, 17, 2015, 250.
34. [34] Wang, Y., Dou, H., Liu, G., Yu, L., Chen, S., Min, Y., et al. Hepatitis C virus infection and the risk of Sjögren or sicca syndrome: a meta-analysis. Microbiol Immunol 58 (2014), 675–687.
35. [35] Ramos-Casals, M., Loustaud-Ratti, V., De Vita, S., Zeher, M., Bosch, J.A., Toussirot, E., et al. Sjögren syndrome associated with hepatitis C virus: a multicenter analysis of 137 cases. Medicine 84 (2005), 81–89.
36. [36] Zeron, P.B., Retamozo, S., Bové, A., Kostov, B.A., Sisó, A., Ramos-Casals, M., Diagnosis of liver involvement in primary Sjögren syndrome. J Clin Transl Hepatol 1 (2013), 94–102.
37. [37] Ramos-Casals, M., la Civita, L., de Vita, S., Solans, R., Luppi, M., Medina, F., et al. Characterization of B cell lymphoma in patients with Sjögren's syndrome and hepatitis C virus infection. Arthritis Rheum 57 (2007), 161–170.
38. [38] Retamozo, S., Gheitasi, H., Quartuccio, L., Kostov, B., Corazza, L., Bové, A., et al. Cryoglobulinaemic vasculitis at diagnosis predicts mortality in primary Sjögren syndrome: analysis of 515 patients. Rheumatology, 2016 [pii: kew194].
39. [39] Karim, Z., Lyoumi, S., Nicolas, G., Deybach, J.C., Gouya, L., Puy, H., Porphyrias: a 2015 update. Clin Res Hepatol Gastroenterol 39 (2015), 412–425.
40. [40] Dedania, B., Wu, G.Y., Dermatologic extrahepatic manifestations of hepatitis C. J Clin Transl Hepatol 3 (2015), 127–133.
41. [41] Fargion, S., Piperno, A., Cappellini, M.D., Sampietro, M., Fracanzani, A.L., Romano, R., et al. Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association. Hepatology 16 (1992), 1322–1326.
42. [42] Ferri, C., Baicchi, U., La Civita, L., Greco, F., Longombardo, G., Mazzoni, A., et al. Hepatitis C virus-related autoimmunity in patients with porphyria cutanea tarda. Eur J Clin Invest 23 (1993), 851–855.
43. [43] Gisbert, J.R., Garcla-Buey, L., Pajares, J.M., Moreno-Otero, R., Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol 39 (2003), 620–627.
44. [44] Ferri, C., La Civita, L., Caracciolo, F., Zignego, A.L., Non-Hodgkin's lymphoma: possible role of hepatitis C virus. JAMA 272 (1994), 355–356.
45. [45] Dal Maso, L., Franceschi, S., Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev 15 (2006), 2078–2085.
46. [46] Chuang, S.S., Liao, Y.L., Chang, S.T., Hsieh, Y.C., Kuo, S.Y., Lu, C.L., et al. Hepatitis C virus infection is significantly associated with malignant lymphoma in Taiwan, particularly with nodal and splenic marginal zone lymphomas. J Clin Pathol 63 (2010), 595–598.
47. [47] de Sanjose, S., Benavente, Y., Vajdic, C.M., Engels, E.A., Morton, L.M., Bracci, P.M., et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol 6 (2008), 451–458.
48. [48] Arcaini, L., Burcheri, S., Rossi, A., Paulli, M., Bruno, R., Passamonti, F., et al. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Ann Oncol 18 (2007), 346–350.
49. [49] Arcaini, L., Rossi, D., Lucioni, M., Nicola, M., Bruscaggin, A., Fiaccadori, V., et al. The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection. Haematologica 100 (2015), 246–252.
50. [50] Arcaini, L., Lazzarino, M., Colombo, N., Burcheri, S., Boveri, E., Paulli, M., et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood 107 (2006), 4643–4649.
51. [51] Thieblemont, C., Felman, P., Berger, F., Dumontet, C., Arnaud, P., Hequet, O., et al. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin Lymphoma 3 (2002), 41–47.
52. [52] Saadoun, D., Suarez, F., Lefrere, F., Valensi, F., Mariette, X., Aouba, A., et al. Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity?. Blood 105 (2005), 74–76.
53. [53] Ambrosetti, A., Zanotti, R., Pattaro, C., Lenzi, L., Chilosi, M., Caramaschi, P., et al. Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjogren syndrome or hepatitis C virus infection. Br J Haematol 126 (2008), 43–49.
54. [54] Arnaud, P., Escande, M.C., Lecuit, M., Validire, P., Levy, C., Plancher, C., et al. Hepatitis C virus infection and MALT-type ocular adnexal lymphoma. Ann Oncol 18 (2007), 400–401 [author reply 401–403].
55. [55] Ferreri, A.J., Viale, E., Guidoboni, M., Resti, A.G., De Conciliis, C., Politi, L., et al. Clinical implications of hepatitis C virus infection in MALT-type lymphoma of the ocular adnexa. Ann Oncol 17 (2006), 769–772.
56. [56] Mollejo, M., Menarguez, J., Guisado-Vasco, P., Bento, L., Algara, P., Montes-Moreno, S., et al. Hepatitis C virus-related lymphoproliferative disorders encompass a broader clinical and morphological spectrum than previously recognized: a clinicopathological study. Mod Pathol 27 (2014), 281–293.
57. [57] Besson, C., Canioni, D., Lepage, E., Pol, S., Morel, P., Lederlin, P., et al. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs. J Clin Oncol 24 (2006), 953–960.
58. [58] Merli, M., Visco, C., Spina, M., Luminari, S., Ferretti, V.V., Gotti, M., et al. Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. Haematologica 99 (2014), 489–496.
59. [59] Michot, J.M., Canioni, D., Driss, H., Alric, L., Cacoub, P., Suarez, F., et al., ANRS HC-13 Lympho-C Study Group, Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study. Am J Hematol 90 (2015), 197–203.
60. [60] Visco, C., Arcaini, L., Brusamolino, E., Burcheri, S., Ambrosetti, A., Merli, M., et al. Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. Ann Oncol 17 (2006), 1434–1440.
61. [61] Swerdlow, S.H., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J., et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 2008, IARC Press, Lyon.
62. [62] Fazi, C., Dagklis, A., Cottini, F., Scarfo, L., Bertilaccio, M.T., Finazzi, R., et al. Monoclonal B cell lymphocytosis in hepatitis C virus infected individuals. Cytometry B Clin Cytom 78:Suppl. 1 (2010), S61–S68.
63. [63] Matutes, E., Oscier, D., Montalban, C., Berger, F., Callet-Bauchu, E., Dogan, A., et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia 22 (2008), 487–495.
64. [64] Tawfik, N.M., El Deeb, M., Nasr, A.S., Monoclonal gammopathy among patients with chronic hepatitis C virus infection. Am J Med Sci 345 (2013), 366–368.
65. [65] Mangia, A., Clemente, R., Musto, P., Cascavilla, I., La Floresta, P., Sanpaolo, G., et al. Hepatitis C virus infection and monoclonal gammopathies not associated with cryoglobulinemia. Leukemia 10 (1996), 1209–1213.
66. [66] Andreone, P., Zignego, A.L., Cursaro, C., Gramenzi, A., Gherlinzoni, F., Fiorino, S., et al. Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection. Ann Intern Med 129 (1998), 294–298.
67. [67] Cheson, B.D., Fisher, R.I., Barrington, S.F., Cavalli, F., Schwartz, L.H., Zucca, E., et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32 (2014), 3059–3068.
68. [68] Dreyling, M., Thieblemont, C., Gallamini, A., Arcaini, L., Campo, E., Hermine, O., et al. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol 24 (2013), 857–877.
69. [69] APaulli, M., Arcaini, L., Lucioni, M., Boveri, E., Capello, D., Passamonti, F., et al. Subcutaneous ‘lipoma-like’ B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT. Ann Oncol 21 (2009), 1189–1195.
70. [70] Lerat, H., Rumin, S., Habersetzer, F., Berby, F., Trabaud, M.A., Trépo, C., et al. In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: influence of viral load, viral genotype, and cell phenotype. Blood 91 (1998), 3841–3849.
71. [71] Wang, C.S., Yao, W.J., Wang, S.T., Chang, T.T., Chou, P., Strong association of hepatitis C virus (HCV) infection and thrombocytopenia: implications from a survey of a community with hyperendemic HCV infection. Clin Infect Dis 39 (2004), 790–796.
72. [72] Ramos-Casals, M., García-Carrasco, M., López-Medrano, F., Trejo, O., Forns, X., López-Guillermo, A., et al. Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 35 cases. Medicine 82 (2003), 87–96.
73. [73] Dufour, J.F., Pradat, P., Ruivard, M., Hot, A., Dumontet, C., Broussolle, C., et al. Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 16 cases. Eur J Gastroenterol Hepatol 21 (2009), 245–253.
74. [74] Chiao, E.Y., Engels, E.A., Kramer, J.R., Pietz, K., Henderson, L., Giordano, T.P., et al. Risk of immune thrombocytopenic purpura and autoimmune hemolytic anemia among 120 908 US veterans with hepatitis C virus infection. Arch Intern Med 169 (2009), 357–363.
75. [75] Roccatello, D., Fornasieri, A., Giachino, O., Rossi, D., Beltrame, A., Banfi, G., et al. Multicenter study on HCV-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis 49 (2007), 69–82.
76. [76] Caussin-Schwemling, C., Schmitt, C., Stoll-Keller, F., Study of the infection of human blood derived monocyte/macrophages with hepatitis C virus in vitro. J Med Virol 65 (2001), 14–22.
77. [77] Ito, M., Murakami, K., Suzuki, T., Mochida, K., Suzuki, M., Ikebuchi, K., et al. Enhanced expression of lymphomagenesis-related genes in peripheral blood B cells of chronic hepatitis C patients. Clin Immunol 135 (2010), 459–465.
78. [78] Muramatsu, M., Kinoshita, K., Fagarasan, S., Yamada, S., Shinkai, Y., Honjo, T., Class switch recombination and hypermutation required activation-induced cytidine deaminase, a potential RNA editing enzyme. Cell 102 (2000), 553–563.
79. [79] Roccatello, D., Morsica, G., Picciotto, G., Cesano, G., Ropolo, R., Bernardi, M.T., et al. Impaired hepatosplenic elimination of circulating cryoglobulins in patients with essential mixed cryoglobulinemia and hepatitis C virus (HCV) infection. Clin Exp Immunol 110 (1997), 9–14.
80. [80] Roccatello, D., Isidoro, C., Mazzucco, G., Mesiti, A., Quattrocchio, G., Amore, A., et al. Role of monocytes in cryoglobulinemia-associated nephritis. Kidney Int 43 (1993), 1150–1155.
81. [81] Guo, S., Wietecha, T.A., Hudkins, K.L., Kida, Y., Spencer, M.W., Pichaiwong, W., et al. Macrophages are essential contributors to kidney injury in murine cryoglobulinemic membranoproliferative glomerulonephritis. Kidney Int 80 (2011), 946–958.
82. [82] Roccatello, Pani, A., Fervenza, F., (eds.) Cryoglobulinemias in core concepts in parenchimal kidney diseases, 2014, Springer Sciences, New York.
83. [83] Antonelli, A., Ferri, C., Pampana, A., Fallahi, P., Nesti, C., Pasquini, M., et al. Thyroid disorders in chronic hepatitis C. Am J Med 117 (2004), 10–13.
84. [84] Antonelli, A., Ferri, C., Fallahi, P., Hepatitis C: thyroid dysfunction in patients with hepatitis C on IFN-alpha therapy. Nat Rev Gastroenterol Hepatol 6 (2009), 633–635.
85. [85] Antonelli, A., Ferri, C., Fallahi, P., Ferrari, S.M., Frascerra, S., Sebastiani, M., et al. High values of CXCL10 serum levels in patients with hepatitis C associated mixed cryoglobulinemia in presence or absence of autoimmune thyroiditis. Cytokine 42 (2008), 137–143.
86. [86] Fallahi, P., Ferrari, S.M., Ruffilli, I., Elia, G., Giuggioli, D., Colaci, M., et al. Incidence of thyroid disorders in mixed cryoglobulinemia: Results from a longitudinal follow-up. Autoimmun Rev 15 (2016), 747–751.
87. [87] Antonelli, A., Ferri, C., Fallahi, P., Nesti, C., Zignego, A.L., Maccheroni, M., Thyroid cancer in HCV-related mixed cryoglobulinemia patients. Clin Exp Rheumatol 20 (2002), 693–696.
88. [88] Fallahi, P., Ferrari, S.M., Politti, U., Giuggioli, D., Ferri, C., Antonelli, A., Autoimmune and neoplastic thyroid diseases associated with hepatitis C chronic infection. Int J Endocrinol, 2014, 2014, 935131.
89. [89] Mason, A.L., Lau, J.Y., Hoang, N., Qian, K., Alexander, G.J., Xu, L., et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 29 (1999), 328–333.
90. [90] Weinman, S.A., Belalcazar, L.M., Hepatitis C: a metabolic liver disease. Gastroenterology 126:3 (2004 Mar), 917–919.
91. [91] Bugianesi, E., McCullough, A.J., Marchesini, G., Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 42 (2005), 987–1000.
92. [92] Allison, M.E., Wreghitt, T., Palmer, C.R., Alexander, G.J., Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 21 (1994), 1135–1139.
93. [93] Antonelli, A., Ferri, C., Fallahi, P., Sebastiani, M., Nesti, C., Barani, L., et al. Type 2 diabetes in hepatitis C-related mixed cryoglobulinaemia patients. Rheumatology 43 (2004), 238–240.
94. [94] Antonelli, A., Ferri, C., Fallahi, P., Pampana, A., Ferrari, S.M., Goglia, F., et al. Hepatitis C virus infection: evidence for an association with type 2 diabetes. Diabetes Care 28 (2005), 2548–2550.
95. [95] Konrad, T., Zeuzem, S., Vicini, P., Toffolo, G., Briem, D., Lormann, J., et al. Evaluation of factors controlling glucose tolerance in patients with HCV infection before and after 4 months therapy with interferon-alpha. Eur J Clin Invest 30 (2000), 111–121.
96. [96] Chen, C.L., Yang, H.I., Yang, W.S., Liu, C.J., Chen, P.J., You, S.L., et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 135 (2008), 111–121.
97. [97] Ferri, C., Cutolo, M., Zignego, A.L., Longombardo, G., Sulli, A., Cavallaro, D., et al. Role of androgens in HCV-related mixed cryoglobulinemia. Arthritis Rheum, 41, 1998, S539.
98. [98] Malaguarnera, M., Vicari, E., Calogero, A., Cammalleri, L., Di Fazio, I., Gargante, M.P., et al. Sexual dysfunction in chronic hepatitis C virus patients treated with interferon alpha and ribavirin. J Interferon Cytokine Res 28 (2008), 603–609.
99. [99] Fusco, F., D'Anzeo, G., Rossi, A., Sciorio, C., Buonomo, A.R., d'Emmanuele di VillaBianca, R., et al. Erectile dysfunction in patients with chronic viral hepatitis: a systematic review of the literature. Expert Opin Pharmacother 14 (2013), 2533–2544.
100. [100] Ferri, C., Bertozzi, M.A., Zignego, A.L., Erectile dysfunction and hepatitis C virus infection. JAMA 288 (2002), 698–699.
101. [101] Crook, E.D., Penumalee, S., Gavini, B., Filippova, K., Hepatitis C Is a Predictor of Poorer Renal Survival in Diabetic Patients. Diabetes Care 28 (2005), 2187–2191.
102. [102] Ferri, C., La Civita, L., Cirafisi, C., Siciliano, G., Longombardo, G., Bombardieri, S., et al. Peripheral neuropathy in mixed cryoglobulinemia: clinical and electrophysiologic investigations. J Rheumatol 19 (1992), 889–895.
103. [103] Cacoub, P., Saadoun, D., Limal, N., Léger, J.M., Maisonobe, T., Hepatitis C virus infection and mixed cryoglobulinaemia vasculitis: a review of neurological complications. AIDS 19 (2005), S128–S134.
104. [104] Mathew, S., Faheem, M., Ibrahim, S.M., Iqbal, W., Rauff, B., Fatima, K., et al. Hepatitis C virus and neurological damage. World J Hepatol 8 (2016), 545–556.
105. [105] Adinolfi, L.E., Nevola, R., Lus, G., Restivo, L., Guerrera, B., Romano, C., et al. Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview. World J Gastroenterol 21 (2015), 2269–2280.
106. [106] Monaco, S., Mariotto, S., Ferrari, S., Calabrese, M., Zanusso, G., Gajofatto, A., et al. Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: advances in 2015. World J Gastroenterol 21 (2015), 11974–11983.
107. [107] Lidove, O., Cacoub, P., Maisonobe, T., Servan, J., Thibault, V., Piette, J.C., et al. Hepatitis C virus infection with peripheral neuropathy is not always associated with cryoglobulinaemia. Ann Rheum Dis 60 (2001), 290–292.
108. [108] Casato, M., Saadoun, D., Marchetti, A., Limal, N., Picq, C., Pantano, P., et al. Central nervous system involvement in hepatitis C virus cryoglobulinemia vasculitis: a multicenter case–control study using magnetic resonance imaging and neuropsychological tests. J Rheumatol 32 (2005), 484–488.
109. [109] Ito, H., Ito, H., Nagano, M., Nakano, S., Shigeyoshi, Y., Kusaka, H., In situ identification of hepatitis C virus RNA in muscle. Neurology 64 (2005), 1073–1075.
110. [110] Saadoun, D., Bieche, I., Authier, F.J., Laurendeau, I., Jambou, F., Piette, J.C., et al. Role of matrix metalloproteinases, proinflammatory cytokines, and oxidative stress-derived molecules in hepatitis C virus-associated mixed cryoglobulinemia vasculitis neuropathy. Arthritis Rheum 56 (2007), 1315–1324.
111. [111] Alpa, M., Ferrero, B., Cavallo, R., Naretto, C., Menegatti, E., Di Simone, D., et al. Anti-neuronal antibodies in patients with HCV-related mixed cryoglobulinemia. Autoimmun Rev 8 (2008), 56–58.
112. [112] Lucaciu, L.A., Dumitrascu, D.L., Depression and suicide ideation in chronic hepatitis C patients untreated and treated with interferon: prevalence, prevention, and treatment. Ann Gastroenterol 28 (2015), 440–447.
113. [113] Boonyapisit, K., Katirji, B., Severe exacerbation of hepatitis C-associated vasculitic neuropathy following treatment with interferon alpha: a case report and literature review. Muscle Nerve 25 (2002), 909–913.
114. [114] Fattovich, G., Giustina, G., Favarato, S., Ruol, A., A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 24 (1996), 38–47.
115. [115] Herrmann, D.N., McDermott, M.P., Henderson, D., Chen, L., Akowuah, K., Schifitto, G., North East AIDS Dementia (NEAD) Consortium, Epidermal nerve fiber density, axonal swellings and QST as predictors of HIV distal sensory neuropathy. Muscle Nerve 29 (2004), 420–427.
116. [116] Gemignani, F., Brindani, F., Alfieri, S., Giuberti, T., Allegri, I., Ferrari, C., et al. Clinical spectrum of cryoglobulinaemic neuropathy. J Neurol Neurosurg Psychiatry 76 (2005), 1410–1414.
117. [117] Abdel Razek, A.A., Alvarez, H., Bagg, S., Refaat, S., Castillo, M., Imaging spectrum of CNS vasculitis. Radiographics 34 (2014), 873–894.
118. [118] Küker, W., Cerebral vasculitis: imaging signs revisited. Neuroradiology 49 (2007), 471–479.
119. [119] Heeren, M., Sojref, F., Schuppner, R., Worthmann, H., Pflugrad, H., Tryc, A.B., et al. Active at night, sleepy all day–sleep disturbances in patients with hepatitis C virus infection. J Hepatol 60 (2014), 732–740.
120. [120] Chaudhary, M., Sharma, M., Management of psychological effects through counselling during HCV (hepatitis) treatment. Int J Indian Psychol 3 (2016), 106–112.
121. [121] Ishizaka, N., Ishizaka, Y., Takahashi, E., Tooda, E., Hashimoto, H., Nagai, R., et al. Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. Lancet 359 (2002), 133–135.
122. [122] Adinolfi, L.E., Zampino, R., Restivo, L., Lonardo, A., Guerrera, B., Marrone, A., et al. Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. World J Gastroenterol 20 (2014), 3410–3417.
123. [123] Terrier, B., Karras, A., Cluzel, P., Collet, J.P., Sène, D., Saadoun, D., et al. Presentation and prognosis of cardiac involvement in hepatitis C virus-related vasculitis. Am J Cardiol 111 (2013), 265–272.
124. [124] Domont, F., Cacoub, P., Chronic hepatitis C virus infection, a new cardiovascular risk factor?. Liver Int 36 (2016), 621–627.
125. [125] El-Kamary, S.S., Jhaveri, R., Shardell, M.D., All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population. Clin Infect Dis 53 (2011), 150–157.
126. [126] Bartoloni, E., Shoenfeld, Y., Gerli, R., Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: two faces of the same coin. Arthritis Care Res 63 (2011), 178–183.
127. [127] Campbell, L.A., Rosenfeld, M.E., Infection and atherosclerosis development. Arch Med Res 46 (2015), 339–350.
128. [128] Zampino, R., Marrone, A., Restivo, L., Guerrera, B., Sellitto, A., Rinaldi, L., et al. Chronic HCV infection and inflammation: clinical impact on hepatic and extra-hepatic manifestations. World J Hepatol 5 (2013), 528–540.
129. [129] Boddi, M., Abbate, R., Chellini, B., Giusti, B., Giannini, C., Pratesi, G., et al. Hepatitis C virus RNA localization in human carotid plaques. J Clin Virol 47 (2010), 72–75.
130. [130] Cacoub, P., Lunel-Fabiani, F., Du, L.T., Polyarteritis nodosa and hepatitis C virus infection. Ann Intern Med 116 (1992), 605–606.
131. [131] Ramos-Casals, M., Font, J., García-Carrasco, M., Cervera, R., Jiménez, S., Trejo, O., et al. Hepatitis C virus infection mimicking systemic lupus erythematosus: study of hepatitis C virus infection in a series of 134 Spanish patients with systemic lupus erythematosus. Arthritis Rheum 43 (2000), 2801–2806.
132. [132] Ahmed, M.M., Berney, S.M., Wolf, R.E., Hearth-Holmes, M., Hayat, S., Mubashir, E., et al. Prevalence of active hepatitis C virus infection in patients with systemic lupus erythematosus. Am J Med Sci 331 (2006), 252–256.
133. [133] Chen, M.H., Chen, M.H., Tsai, C.Y., Chou, C.T., Lin, H.Y., Huang, D.F., et al. Incidence and antiviral response of hepatitis C virus reactivation in lupus patients undergoing immunosuppressive therapy. Lupus 24 (2015), 1029–1036.
134. [134] Perlemuter, G., Cacoub, P., Sbaï, A., Hausfater, P., Thibault, V., Le, T.H., et al. Hepatitis C virus infection in systemic lupus erythematosus: a case–control study. J Rheumatol 30 (2003), 1473–1478.
135. [135] Ramos-Casals, M., Muñoz, S., Medina, F., Jara, L.J., Rosas, J., Calvo-Alen, J., et al. Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry). J Rheumatol 36 (2009), 1442–1448.
136. [136] Saadoun, D., Terrier, B., Semoun, O., Sene, D., Maisonobe, T., Musset, L., et al. Hepatitis C virus-associated polyarteritis nodosa. Arthritis Care Res 63 (2011), 427–435.
137. [137] Ramos-Casals, M., Jara, L.J., Medina, F., Rosas, J., Calvo-Alen, J., Mañá, J., et al. Systemic autoimmune diseases co-existing with chronic hepatitis C virus infection (the HISPAMEC Registry): patterns of clinical and immunological expression in 180 cases. J Intern Med 257 (2005), 549–557.
138. [138] Uruha, A., Noguchi, S., Hayashi, Y.K., Tsuburaya, R.S., Yonekawa, T., Nonaka, I., et al. Hepatitis C virus infection in inclusion body myositis: A case–control study. Neurology 86 (2016), 211–217.
139. [139] Ramos-Casals, M., Mañá, J., Nardi, N., Brito-Zerón, P., Xaubet, A., Sánchez-Tapias, J.M., et al., HISPAMEC Study Group, Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases. Medicine 84 (2005), 69–80.
140. [140] Ramos-Casals, M., Cervera, R., Lagrutta, M., Medina, F., García-Carrasco, M., de la Red, G., et al. Clinical features related to antiphospholipid syndrome in patients with chronic viral infections (hepatitis C virus/HIV infection): description of 82 cases. Clin Infect Dis 38 (2004), 1009–1016.
141. [141] Garcovich, S., Garcovich, M., Capizzi, R., Gasbarrini, A., Zocco, M.A., Cutaneous manifestations of hepatitis C in the era of new antiviral agents. World J Hepatol 7 (2015), 2740–2748.
142. [142] Imafuku, S., Naito, R., Nakayama, J., Possible association of hepatitis C virus infection with late-onset psoriasis: a hospital-based observational study. J Dermatol 40 (2013), 813–818.
143. [143] Kanada, K.N., Schupp, C.W., Armstrong, A.W., Association between psoriasis and viral infections in the United States: focusing on hepatitis B, hepatitis C and human immunodeficiency virus. J Eur Acad Dermatol Venereol 27 (2013), 1312–1316.
144. [144] Wilson, S.E., Lee, W.M., Murakami, C., Weng, J., Moninger, G.A., Mooren-type hepatitis C virus-associated corneal ulceration. Ophthalmology 101 (1994), 736–745.
145. [145] Aliannejad, R., Ghanei, M., Hepatitis C and pulmonary fibrosis: Hepatitis C and pulmonary fibrosis. Hepat Mon 11 (2011), 71–73.
146. [146] Kozanoglu, E., Canataroglu, A., Abayli, B., Colakoglu, S., Goncu, K., Fibromyalgia syndrome in patients with hepatitis C infection. Rheumatol Int 23 (2003), 248–251.
147. [147] Narvaez, J., Nolla, J.M., Valverde-Garciala, J., Lack of association of fibromyalgia with hepatitis C virus infection. J Rheumatol 32 (2005), 1118–1121.
148. [148] Ferri, C., Manfredi, A., Sebastiani, M., Colaci, M., Giuggioli, D., Vacchi, C., et al. Interstitial pneumonia with autoimmune features and undifferentiated connective tissue disease: our interdisciplinary rheumatology-pneumology experience, and review of the literature. Autoimmun Rev 15 (2016), 61–70.
149. [149] Ramos-Casals, M., Font, J., Extrahepatic manifestations in patients with chronic hepatitis C virus infection. Curr Opin Rheumatol 17 (2005), 447–455.
150. [150] Zignego, A.L., Macchia, D., Monti, M., Thiers, V., Mazzetti, M., Foschi, M., et al. Infection of peripheral mononuclear blood cells by hepatitis C virus. J Hepatol 15 (1992), 382–386.
151. [151] Ferri, C., Monti, M., La Civita, L., Longombardo, G., Greco, F., Pasero, G., et al. Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia. Blood 82 (1993), 3701–3704.
152. [152] Gragnani, L., Visentini, M., Fognani, E., Urraro, T., De Santis, A., Petraccia, L., et al. Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. Hepatology, 2016 Aug 1, 10.1002/hep.28753 [Epub ahead of print].
153. [153] Buskila, D., Shnaider, A., Neumann, L., Lorber, M., Zilberman, D., Hilzenrat, N., et al. Musculoskeletal manifestations and autoantibody profile in 90 hepatitis C virus infected Israeli patients. Semin Arthritis Rheum 28 (1998), 107–113.
154. [154] Cacoub, P., Poynard, T., Ghillani, P., Charlotte, F., Olivi, M., Piette, J.C., et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum 42 (1999), 2204–2212.
155. [155] Cacoub, P., Renou, C., Rosenthal, E., Cohen, P., Loury, I., Loustaud-Ratti, V., et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. Medicine 79 (2000), 47–56.
156. [156] Zignego, A.L., Gragnani, L., Piluso, A., Sebastiani, M., Giuggioli, D., Fallahi, P., et al. Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection. Expert Rev Clin Immunol 11 (2015), 15–31.
157. [157] Stefanova-Petrova, D.V., Tzvetanska, A.H., Naumova, E.J., Mihailova, A.P., Hadjiev, E.A., Dikova, R.P., et al. Chronic hepatitis C virus infection: prevalence of extrahepatic manifestations and association with cryoglobulinemia in Bulgarian patients. World J Gastroenterol 13 (2007), 6518–6528.
158. [158] Mohammed, R.H., ElMakhzangy, H.I., Gamal, A., Mekky, F., El Kassas, M., Mohammed, N., et al. Prevalence of rheumatologic manifestations of chronic hepatitis C virus infection among Egyptians. Clin Rheumatol 29 (2010), 1373–1380.
159. [159] Kahloun, A., Babba, T., Fathallah, B., Ghozzi, M., Ezzine, H., Said, Y., et al. Prevalence of extra-hepatic manifestations in infection with hepatitis C virus: study of 140 cases. Tunis Med 89 (2011), 557–560.
160. [160] Cheng, Z., Zhou, B., Shi, X., Zhang, Y., Zhang, L., Chen, L., et al. Extrahepatic manifestations of chronic hepatitis C virus infection: 297 cases from a tertiary medical center in Beijing, China. Chin Med J (Engl) 127 (2014), 1206–1210.
161. [161] Sene, D., Ghillani-Dalbin, P., Thibault, V., Guis, L., Musset, L., Duhaut, P., et al. Longterm course of mixed cryoglobulinemia in patient infected with hepatitis C virus. J Rheumatol 31 (2004), 2199–2206.
162. [162] Terrier, B., Sène, D., Dechartres, A., Saadoun, D., Ortonne, N., Rouvier, P., et al. Systemic vasculitis in patients with hepatitis C virus infection with and without detectable mixed cryoglobulinemia. J Rheumatol 38 (2011), 104–110.
163. [163] Lidar, M., Lipschitz, N., Agmon-Levin, N., Langevitz, P., Barzilai, O., Ram, M., et al. Infectious serologies and autoantibodies in hepatitis C and autoimmune disease-associated mixed cryoglobulinemia. Clin Rev Allergy Immunol 42 (2012), 238–246.
164. [164] González-Grande, R., Jiménez-Pérez, M., González Arjona, C., Mostazo, T.J., New approaches in the treatment of hepatitis C. World J Gastroenterol 22 (2016), 1421–1432.
165. [165] Zopf, S., Kremer, A.E., Neurath, M.F., Siebler, J., Advances in hepatitis C therapy: what is the current state—what come's next?. World J Hepatol 8 (2016), 139–147.
166. [166] Saadoun, D., Thibault, V., Si Ahmed, S.N., Alric, L., Mallet, M., Guillaud, C., et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis, 2015, 10.1136/annrheumdis-2015-208339.